Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.
By E. Abalos, L. Duley, D. Steyn, D. Henderson‐Smart. Cochrane Database of Systematic Reviews, 2014
776 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Obstetrics and Gynecology, Pediatrics, Perinatology and Child Health
View Paper: https://www.semanticscholar.org/paper/d3c6da4df80e39b1df1e96a3c324f029a157cc37
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- S. Laurent
- Paulus Kirchhof
- C. Bushnell
- E. Schiffrin
- H. S. Boudier
- V. Basevi
- Massimo F. Piepoli
- B. K. Pedersen
In Obstetrics and Gynecology
In Pediatrics, Perinatology and Child Health
Citations in the corpus
- Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy (2003, background): “There has been no reduction in perinatal mortality, placental abruption, or superimposed preeclampsia (56,57).”
- The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “SBP or >110 mmHgfor DBP) is required and beneficial, the benefits of antihypertensive therapy are uncertain for mildly to moderately elevated BP in pregnancy (<160/ 110 mmHg), either preexisting or pregnancy-induced, except for a lower risk of developing severe hypertension [500].”
- Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2014, methodology): “CCBs appear to be safe in pregnancy, with the most commonly used CCB being nifedipine.(132,133) A 2007 Cochrane review indicated that there was a small increase in the risk for preeclampsia with the use of CCBs versus no therapy (725 women; RR, 1.”
- 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, background): “SBP or >110mmHgfor DBP) is required and beneficial, the benefits of antihypertensive therapy are uncertain for mildly to moderately elevated BP in pregnancy (<160/ 110mmHg), either preexisting or pregnancy-induced, except for a lower risk of developing severe hypertension [500].”
- 2013 ESH/ESC Guidelines for the management of arterial hypertension (2007, background): “SBP or >110 mmHgfor DBP) is required and beneficial, the benefits of antihypertensive therapy are uncertain for mildly to moderately elevated BP in pregnancy (<160/ 110 mmHg), either preexisting or pregnancy-induced, except for a lower risk of developing severe hypertension [500].”
- Diabetes and Hypertension: A Position Statement by the American Diabetes Association (2017, background): “A Cochrane systematic review did not find conclusive evidence for or against blood pressure treatment for mild to moderate preexisting hypertension to reduce the risk of preeclampsia, preterm birth, small-for-gestational-age infants, or fetal death (113).”
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) (2019, background): “In the systemic review of Cochrane Library in 2014, no significant influence of antihypertensive drug use was shown on any of maternal mortality, eclampsia, proteinuria, maternal adverse reactions, progression to pre-eclampsia, cesarean section, fetal/neonatal mortality, premature labor (<37 weeks),”